Skip to Content
Merck
All Photos(1)

Documents

Y0000306

Azithromycin

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Azithromycin dihydrate, 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10- trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylohexopyranosyl]oxy]-, dihydrate, [2R-(2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)]-, N-Methyl-11-aza-10-deoxo-10-dihydroerythromycin A, CP-62993

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C38H72N2O12 · 2H2O
CAS Number:
117772-70-0
Molecular Weight:
785.02
MDL number:
MFCD01862248
UNSPSC Code:
41116107
PubChem Substance ID:
329830903
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

azithromycin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O.O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

1S/C38H72N2O12.2H2O/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28;;/h20-33,35,41-43,45-46H,15-19H2,1-14H3;2*1H2/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-;;/m1../s1

InChI key

SRMPHJKQVUDLQE-KUJJYQHYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Azithromycin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Azithromycin dihydrate is a macrolide antibiotic, azalide subclass. It binds to the 50S subunit of the 70S bacterial ribosomes and inhibits RNA-dependent protein synthesis in bacterial cells. Azithromycin also has anti-immunomodulatory/anti-inflammatory properties, which make it useful in treating cystic fibrosis.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000637

Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000641

Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard

1046067

Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard

Y0000307

Azithromycin impurity A, European Pharmacopoeia (EP) Reference Standard

1046090

Azithromycin N-oxide, United States Pharmacopeia (USP) Reference Standard

1046045

Azithromycin Related Compound F, United States Pharmacopeia (USP) Reference Standard

1045600

Azaerythromycin A, United States Pharmacopeia (USP) Reference Standard

1046078

Desosaminylazithromycin, United States Pharmacopeia (USP) Reference Standard

1046089

N-Demethylazithromycin, United States Pharmacopeia (USP) Reference Standard

1046023

Azithromycin Related Compound H, United States Pharmacopeia (USP) Reference Standard

PHR2625

Desosaminylazithromycin, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2780

Azaerythromycin A, certified reference material, pharmaceutical secondary standard

PHR2781

3′-N-Demethyl-3′-N-formylazithromycin, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2782

Azithromycin N-oxide, certified reference material, pharmaceutical secondary standard

Pictograms

Health hazardEnvironment
GHS08,GHS09

Signal Word

Danger

Hazard Statements

H317,H334,H410

Hazard Classifications

Aquatic Chronic 1 - Resp. Sens. 1 - Skin Sens. 1

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

vibrant-m

M1851000

Metronidazole benzoate

vibrant-m

I0090000

Imipenem

Tetracycline hydrochloride European Pharmacopoeia (EP) Reference Standard

T0600000

Tetracycline hydrochloride

Meropenem trihydrate European Pharmacopoeia (EP) Reference Standard

Y0001252

Meropenem trihydrate

Clarithromycin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1038

Clarithromycin

Ceftriaxone disodium salt hemi(heptahydrate) third-generation cephalosporin antibiotic

Sigma-Aldrich

C5793

Ceftriaxone disodium salt hemi(heptahydrate)

Bezafibrate ≥98%, solid

Sigma-Aldrich

B7273

Bezafibrate

Erythromycin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1039

Erythromycin

Imipenem Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1796

Imipenem

Keith C Meyer et al.
The European respiratory journal, 44(6), 1479-1503 (2014-11-02)
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is associated with poor survival. The International Society for Heart and Lung Transplantation, American Thoracic Society, and European Respiratory Society convened a committee of international experts to describe
Sarah E Burr et al.
Bulletin of the World Health Organization, 92(7), 490-498 (2014-08-12)
To evaluate the effect of repeated mass drug administration (MDA) of azithromycin in the Gambia on the nasopharyngeal carriage of Streptococcus pneumoniae and on the emergence of antibiotic-resistant strains. This study involved villages that participated in a cluster randomized trial
Katharina Krenn et al.
The Journal of thoracic and cardiovascular surgery, 149(4), 1194-1202 (2015-01-18)
Azithromycin has become a standard of care in therapy of bronchiolitis obliterans following lung transplantation. Matrix metalloprotease-9 broncho-alveolar lavage levels increase in airway neutrophilia and bronchiolitis obliterans. Interleukin-17 may play a role in lung allograft rejection, and interleukin-12 is downregulated
Alison M Binder et al.
American journal of respiratory and critical care medicine, 188(7), 807-812 (2013-08-10)
Persons with cystic fibrosis (CF) are at high risk of nontuberculous mycobacterial (NTM) infection, with treatment requiring prolonged multidrug regimens that include macrolides. Although macrolides, specifically azithromycin, are used in the management of patients with CF with chronic Pseudomonas, macrolide-resistant
Josje Altenburg et al.
JAMA, 309(12), 1251-1259 (2013-03-28)
Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF bronchiectasis. To determine the efficacy of macrolide maintenance treatment for adults with non-CF bronchiectasis. The BAT (Bronchiectasis and
View All Related Papers

Protocols

HPLC Analysis of Azithromycin on Ascentis® Express C18 5μm

Separation of Azithromycin, analytical standard

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service